Today's Rundown Arena bags big deal with United for PAH drug ralinepag UniQure’s hemophilia B gene therapy achieves 31% FIX activity Dermavant hires Todd Zavodnick as CEO [Sponsored] Global Life Science Services Platform Unites Under New Name, EVERSANA Nektar nabs Genentech I-O leader Wei Lin to head up its oncology programs [Sponsored] Mining Real-World Data With Cutting-Edge Analytical Tools Cadent Therapeutics bags $40M for neuro pipeline, Bob Dagher as CMO Boehringer Ingelheim and Epizyme launch $300M precision oncology program AbbVie, Mission Therapeutics join forces on Alzheimer’s, Parkinson’s Featured Story | | | Thursday, November 15, 2018 Arena’s run of positive news continues, with a massive $800 million upfront licensing deal with United Therapeutics for its pulmonary artererial hypertension (PAH) drug ralinepag. |
|
|
| This week's sponsor is United for Medical Research. | | | |
Top Stories Thursday, November 15, 2018 UniQure has posted eagerly anticipated data on the modified hemophilia B gene therapy it plans to take into phase 3. The FIX-Padua variant therapy achieved factor IX (FIX) activity levels of 23% to 37%, suggesting it is several times more effective than the version uniQure tested in earlier-phase trials. Thursday, November 15, 2018 Dermavant has named Todd Zavodnick as its CEO. The dermatology-focused Roivant subsidiary hired Zavodnick to fill the role vacated by Jackie Fouse in September. Monday, November 12, 2018 EVERSANA delivers a fully-integrated service portfolio to help life science leaders create value for key constituents across the product lifecycle. Wednesday, November 14, 2018 Nektar Therapeutics has poached Genentech cancer immunotherapy leader Wei Lin, M.D., to head up its oncology program and serve as VP of clinical development as it moves forward with its phase 3 trial with its lead combination therapy. Wednesday, November 14, 2018 In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream. Thursday, November 15, 2018 Cadent Therapeutics is coming out of stealth with a new chief medical officer and $40 million to move three of its programs into phase 2. The Cambridge, Massachusetts-based biotech is targeting ion channels to develop treatments for movement disorders and cognitive impairment. Thursday, November 15, 2018 In a worldwide collaboration worth up to $300 million or more, Boehringer Ingelheim is expanding its precision oncology programs by tapping Epizyme for research into two previously unaddressed regulators of genes linked to cancer. Thursday, November 15, 2018 AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease. By targeting these enzymes, the pair hopes to create drugs that attack the buildup of toxic proteins in these neurodegenerative diseases and stop them from getting worse. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Forte Research Systems Discover what over 800 of your peers think about technology's impact on clinical trial operations. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Compliance Training for Professionals working in APAC region March 4-7, 2019 | Singapore FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami | 